News Release

SARS-CoV-2 antibody response to 2 or 3 doses of BioNTech-Pfizer vaccine in patients with cancer

JAMA Oncology

Peer-Reviewed Publication

JAMA Network

What The Study Did: This study assessed the antibody response to two or three doses of the BioNTech-Pfizer SARS-CoV-2 vaccine in 163 patients treated with anticancer agents for solid tumors.

Authors: Charlotte Fenioux, M.D., of Hôpital Henri Mondor in Créteil, France, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.